Immunoprecise Stock Stock News Today

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Immunoprecise Stock News module provides quick insight into current market opportunities from investing in Immunoprecise Antibodies. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Immunoprecise Antibodies stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Please see Immunoprecise Antibodies Hype Analysis, Immunoprecise Antibodies Correlation and Immunoprecise Antibodies Performance.
  
Refresh
Immunoprecise Antibodies stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immunoprecise daily returns and investor perception about the current pice of Immunoprecise Antibodies as well as its diversification or hedging effects on your existing portfolios.
3 days ago at www.digitaljournal.com         
Biotech Recovery Accelerates These Companies Benefit - Digital Journal
news
over two weeks ago at simplywall.st         
Investors might be losing patience for ImmunoPrecise Antibodies increasing losses, as stock sheds 17...
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
IPAs Subsidiary BioStrand Secures Second VLAIO Research Grant - Yahoo Finance
Yahoo News
over two weeks ago at www.marketscreener.com         
IPAs Subsidiary BioStrand Secures Second VLAIO Research Grant - Marketscreener.com
news
over three weeks ago at www.thedailytimes.com         
Research Antibodies Market - Global Forecasts from 2022 to 2027 - ResearchAndMarkets.com - Maryville...
news
over a month ago at www.marketscreener.com         
ImmunoPrecise Antibodies Form 51-102F3 MATERIAL CHANGE REPORT - Form 6-K - Marketscreener.com
news
over a month ago at www.marketscreener.com         
ImmunoPrecise Antibodies IPAs Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevent...
news
over a month ago at www.marketscreener.com         
ImmunoPrecise Antibodies IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherap...
news
over a month ago at www.marketscreener.com         
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue Adding Arti...
news
over a month ago at www.defenseworld.net         
Insider Buying ImmunoPrecise Antibodies Ltd Senior Officer Acquires C74875.00 in Stock - Defense Wor...
news
over a month ago at www.marketscreener.com         
ImmunoPrecise Antibodies New Platform Integrates Sequence Data and Information from Entire Biosphere...
news
over two months ago at www.businesswire.com         
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year...
businesswire News
over two months ago at finance.yahoo.com         
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation...
Yahoo News
over two months ago at www.bakersfield.com         
ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Confer...
news
over three months ago at www.marketscreener.com         
ImmunoPrecise Antibodies Immunotherapeutic PolyTope from ImmunoPrecise Potently Neutralizes the SARS...
news
There is far too much social signal, news, headlines, and media speculation about Immunoprecise Antibodies that is available to investors today. That information is available publicly through Immunoprecise media outlets and privately through word of mouth or via Immunoprecise internal channels. However, regardless of the origin, that massive amount of Immunoprecise data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunoprecise Antibodies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunoprecise Antibodies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunoprecise Antibodies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunoprecise Antibodies alpha.

Immunoprecise Antibodies Performance against DOW

 Price Growth (%)  
      Timeline 
1
EPS Reported05/08/2020
2
EPS Estimate07/31/2020
3
EPS Reported08/28/2020
4
EPS Estimate10/28/2020
5
EPS Reported12/21/2020
6
Other12/30/2020
7
Other01/06/2021
8
Other01/07/2021
9
EPS Estimate01/28/2021
10
Other02/03/2021
11
Other02/04/2021
12
Other02/08/2021
13
Other02/11/2021
14
Other02/19/2021
15
Other03/04/2021
16
Other03/16/2021
17
EPS Reported03/17/2021
18
Other03/18/2021
19
Other03/25/2021
20
Other04/08/2021
21
Other04/21/2021
22
EPS Estimate04/30/2021
23
Other05/20/2021
24
Other05/25/2021
25
Other06/02/2021
26
ImmunoPrecise Antibodies Ltd falls -7.4200 percent for June ...06/09/2021
27
Other06/15/2021
28
Other06/17/2021
29
Other06/22/2021
30
Other07/15/2021
31
Other07/22/2021
32
EPS Reported07/28/2021
33
Other08/04/2021
34
ImmunoPrecise Antibodies falls 5.96 percent in Light Trading...08/16/2021
35
Other09/03/2021
36
Other09/07/2021
37
Other09/08/2021
38
EPS Reported09/09/2021
39
ImmunoPrecise Antibodies falls 2.34 percent to Close at 5.85...10/05/2021
40
Other10/07/2021
41
Other10/13/2021
42
EPS Estimate10/28/2021
43
Other10/29/2021
44
Other11/09/2021
45
Other11/12/2021
46
Research Antibodies Market Size Is Projected to Reach 6.35 B...11/16/2021
47
Other11/24/2021
48
Other11/30/2021
49
ImmunoPrecise Reports Financial Results and Recent Business ...12/07/2021
50
EPS Reported12/13/2021
51
Other12/20/2021
52
ImmunoPrecise Antibodies Announces Grant of Stock Options Bu...01/03/2022
53
Other01/11/2022
54
Other01/18/2022
55
Immunotherapeutic PolyTope from ImmunoPrecise Potently Neutr...01/28/2022
56
EPS Estimate01/31/2022
57
Other03/08/2022
58
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic ...03/14/2022
59
EPS Reported03/16/2022
60
Other03/29/2022
61
Insider Buying ImmunoPrecise Antibodies Ltd Senior Officer A...04/12/2022
62
Other04/14/2022
63
ImmunoPrecise Antibodies IPAs Advanced PolyTope TATX-03, a M...04/20/2022
64
Other04/25/2022
65
IPAs Subsidiary BioStrand Secures Second VLAIO Research Gran...05/06/2022
66
Other05/09/2022
67
Biotech Recovery Accelerates These Companies Benefit - Digit...05/25/2022
Please see Immunoprecise Antibodies Hype Analysis, Immunoprecise Antibodies Correlation and Immunoprecise Antibodies Performance. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.